Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 59 Breast Neoplasms 18 Prostatic Neoplasms 14 Neoplasms 14 Fallopian Tube Neoplasms 13 Neoplasm Metastasis 8 Pancreatic Neoplasms 7 Glioblastoma 7 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 5 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Melanoma 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Mesothelioma, Malignant 2 Mesothelioma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03425201 2024-12-31

NICARAGUA

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1/2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡